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Human embryonic stem cells (hESCs) can provide a unique approach for novel tissue 
engineering applications. Previous groups have shown that hESCs can differentiate into 
specialized cell types through the generation of human embryoid bodies (hEBs). These 
multi-cellular constructs are then subjected to suspension culture for several weeks. 
Traditional hESC differentiation techniques have yielded non-homogeneous EBs derived 
in standard static cultures providing an inefficient platform for cellular viability and 
embryonic modeling. Here, our study aimed at systematically comparing the formation, 
growth, and differentiation capabilities of hESC-derived hEBs in dynamic and static 
suspension cultures. We used a continuous flow perfusion slow turning lateral vessel, 
xi 
 
STLV, system (Synthecon) to model after an in vivo environment. This study is in part of 
a larger study investigating the role of HOXB5 in the human endothelial differentiation 
pathway. Embryoid bodies were created by hanging drops and then subjected to static or 
dynamic culture for 10 days. Cells were harvested and a simple Alkaline Phosphatase 
assay was used to determine if the system was viable for propagating hEB. We show that 
the STLV system is viable for our future studies and this system more efficient at 
maintaining hEBs.  
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CHAPTER 1 - Introduction 
1.1 Motivation  
 Cardiovascular disease, CVD, has the highest morbidity and mortality rates among 
American ailments and causes of death.  Of the estimated 79,400,000 registered 
Americans 1 in 3 have one or more types of CVD. Of these 37,500,000 are estimated to 
be 65 or older (36). Cardiovascular disease is defined as a structural or functional 
abnormality of the heart or of the blood vessels supplying the heart, which impairs its 
normal functioning (1, 5). Advancing feats in cardiac interventions have relied greatly on 
the less invasive therapy, angioplasty, which exceed 1.3 million catherizations per annum 
(36).  More serious revascularization occurrences have been reported annually by the 
American Heart Association, AHA, estimating over 427,000 coronary artery bypass graft, 
CABG procedures performed on more than 249,000 different patients. This procedure is 
considered the gold standard for invasive revascularizng strategies. Although early 
outcome is very promising, about 20%-40% of patients after angioplasty and 5-10% after 
bypass surgery need a renewed surgical intervention within one year because of recurrent 
arterial narrowing (intimal hyperpalasia) or the vessel becomes diseased (24). 
Conventional therapies have used autologous conduits such the radial vein taken from the 
patient’s forearm, the saphenous vein taken from the lower leg, or the mammary artery 
taken from the chest (5). Re-vascularizing therapies present a need for autologous vessels 
that aren’t subject to host rejection (24). When these aren’t available, traditionally, 
patients become fatally ill. Patients having multiple coronary grafting as well as 
peripheral vascular repair and/or replacement are also implicated for the need of 
autologous conduits.  To alleviate the demand of autologous vessels, clinicians and 
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scientists have turned to tissue engineering as a means to combat cardiovascular disease 
(34).  There are an abundant number of investigations into tissue engineering of 
vasculature, however, there are fewer investigations involving human embryonic stem 
cells (hESCs) (2, 3). Thus far there are no reported successes of devices derived from 
human embryonic stem cells. However, hESCs show great promise for regenerative 
therapies aimed at vascular disease (19). This provided the motivation to research blood 
vessel design from an embryologic perspective. 
1.2  Scope of Thesis 
This thesis presented is the initial part of a large planned study on the formation of blood 
islands, the first functional mesoderm cell type derived from differentiated Embryoid 
Bodies of human embryonic stem origins (10). Our hypothesis is that functional vascular 
tissue may be derived from hESC’s by following the steps of blood island formation in 
vitro. As the scope of our background encompasses further investigation into the parent 
project here we report the controls necessary to reach our final question.  Concepts such 
as, blood vessel physiology, embryonic mesoderm development, human embryonic stem 
cells, VEGF, and tissue engineering are discussed in Chapter 1. Chapter 2 includes a 
literature review on the induction of the mesoderm germ layer using hEB formation, 
dynamic culturing, and posses the thesis objective. The experimental design and the 
methodologies of this study are presented in Chapter 3. Chapter 4 reports on the results of 
EB formation in both static and dynamic conditions.  Chapter 5 addresses the studies 
nuances and presents recommending conclusions for continuing the study. 
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1.3 Physiology of a Blood Vessel 
A typical artery wall is comprised of three layers, described from the innermost to outer 
layer they include the tunica intima, the tunica media and the tunica adventitia (1).  The 
intima is composed of a single endothelial cell layer lying on a porous basement 
membrane.  Through this matrix, smooth muscle cells infiltrate from the media into the 
intima.  The basement membrane is a specialized extracellular matrix substrate and 
posses an inner elastic lamina and the interstitial matrix.  The inner elastic lamina mainly 
consists of laminin, type IV collagen, and proteoglycans made from heparin sulphate.  
The interstitial matrix is composed of fibronectin, thrombospondin, collagen I and II, 
chondroitin, dermatan sulphate, proteoglycans and elastin (1).  There is a subendothelial 
layer, underlying the endothelium, and is comprised of fine fibroelastic tissue that is 
mostly longitudinal (3).  The make up of the tunica media is mostly smooth muscle, 
which is arranged circularly.  Elastic fibers are also widely present, but occur in an 
inconsistent pattern (5).  They are arranged in one or more porous layers separated by 
alternating sheets of smooth muscle cells.  The outer casing of the media consists of 
sparse arrangement of elastic tissue and is termed the external elastic lamina (2). The 
media’s nutritional needs are meet through small vessels known as vasa vasorum. The 
outer layer is nourished by diffusion of nutrients from adventitial vessels (1). 
1.4 Human Embryonic Stem Cells, hESC 
Human embryonic stem cells have the potency to differentiate into cells representing all 
three embryonic germ layers ectoderm, endoderm, and the mesoderm (26). Their 
undifferentiated ambiguity makes them an extremely intriguing cell source. Typically 
they have been maintained with a supporting feeder cell layer, such as mouse embryonic 
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fibroblasts (MEFs), to support their undifferentiated growth. These feeder cells not only 
provide secreted extracellular matrix (ECM)  proteins essential for hESC attachment, 
however, they  also contribute to essential nutrients and growth factors to maintain the 
hESC pluripotent character. However, the totality of these components are still widely 
unknown.  In combination with a supporting feeder layer, basic fibroblast growth factor 
(bFGF) is a key component in hESC maintenance media which contributes largely to 
undifferentiated hESC cultures.  In the absence of bFGF, hESCs begin to differentiate 
spontaneously in culture. Directing differentiation relies on current experimental methods 
for the generation of heterogeneous aggregates of cells, also called human embryoid 
bodies, hEB. These structures have traditionally been cultured in small scale static 
cultures. These protocols are typically not scalable and result in a wide range of EB sizes 
and expose cells to fluctuations in physio-chemical parameters. It is important to note that 
traditional hESC cultures involve cell type mixing, either between species  (human and 
mouse) or cell types and results in heterogeneous cell cultures. Culture heterogeneity is a 
serious barrier to cell-based therapy, which relies upon homogenous populations of 
desired differentiated cell types. Cultures where hESCs are intricately mixed with MEFs, 
are especially clinically non-applicable, due to the specific risk of introducing 
immunogenic antigens or cells of a non-human origin. 
1.5  Embryonic Development of the Blood Vessel 
Appropriate activation of the endothelium is also the necessary proximate event for 
growth of new blood vessels from existing vessels during development and in 
physiologic and pathological conditions via the process of angiogenesis. Even earlier in 
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development, the first blood vessels form in situ by migration and differentiation of 
endothelial precursors, or angioblasts, via the process of vasculogenesis. Although 
angiogenesis and vasculogenesis have distinguishing features, the signaling events that 
regulate these processes are, in most cases, overlapping (26, 29). The earliest marker of 
cells fated to the endothelial lineage is the receptor for vascular endothelial growth factor 
(VEGF), fetal liver kinase-1, flk1, (VEGFR-2; the human homolog is also known as 
KDR). Flk1 is first expressed at day 7.0 post conception (p.c.) in the yolk sac mesoderm 
and in the lateral plate mesoderm of the embryo (6). Deletion of flk1 results in absence of 
both endothelial and hematopoietic cells, suggesting that early populations of flk1-
expressing cells define a bipotential precursor for these two lineages (31). This 
conclusion has been supported by the identification of flk1+ blast colony-forming cells 
that give rise to hematopoietic and endothelial lineage progeny during in vitro assays (6). 
These early bipotential cells have been termed hemangioblasts. It is accepted that flk1+ 
cells define a major population of angioblasts and that definitive endothelial cells 
maintain flk1 expression, whereas hematopoietic populations do not (29). 
1.6    Vascular Endothelial Growth Factor (VEGF)  
 Vascular endothelial growth factor is a potent, mobile and specific regulatory  
molecule for vascular endothelial cells and is implicated in the regulation of 
physiological and pathological growth of blood vessels (1). VEGF is a heparin binding 
dimeric glycoprotein and a member of the platelet derived growth factor (PDGF) family.  
It has significant homology to PDGF, and the position of all the eight cysteins found in 
the A and B chains of PDGF are conserved in VEGF (6).  The VEGF family includes 
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several related proteins denoted VEGF-A, -B, -C, -D, -E and the placenta growth factor 
(PIGF).  VEGF-A is represented as VEGF.  Alternative splicing of human VEGF mRNA 
from a single gene containing eight exons gives rise to at least five different isoforms of 
VEGF (31).  Among the isoforms of VEGF, VEGF-165 is the most abundant and is 
typically expressed as a 46-kDa homodimer of two 23-kDa monomers. Exons 1-5 encode 
the core regions essential for binding of the receptors, and VEGF binding sites have been 
identified on the cell surface of vascular endothelial cells in vitro.  VEGF binds to two 
distinct receptor tyrosine kinases (RTKs), referred to as VEGFR1 and VEGFR2 (15).  
Both receptors have seven Ig-like domains in the extracellular domain, a single 
transmembrane region, and a consensus tyrosine kinase sequence that is interrupted by a 
kinase-insert domain.  PIGF and VEGF-B bind to VEGFR-1.  VEGF-C and VEGF-D 
bind to VEGFR-3 (31). 
1.7  HOXB5 
Hox proteins are transcriptional regulators characterized by a 60-amino-acid DNA-
binding domain, the homeodomain (14). The classical Hox proteins exist in four clusters 
(A through D) in mammals, with up to 13 Hox genes in each cluster (16). Their 
expression is dictated by temporal colinearity, with more 3′ genes expressed before the 
corresponding 5′ genes within a cluster (13). Based on studies in both mouse and 
Drosophila, Hox proteins are thought to generally regulate pattern formation and 
segmental identity along the anterior-posterior axis during development. HoxB5 has been 
identified in vascular endothelial cells in culture (15). 
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1.8 Tissue Engineering  
Tissue Engineering offers future promise for the field of cardiovascular tissue 
replacement therapies. It provides the possibility of substantial future savings by 
providing substitutes that are less costly to patients who are in demand for therapeutic 
material such as autologous cells (24). These are obtained from the same individual and 
fated for implantation. These cell types present the path of least resistance in terms device 
rejection or associated pathogens (27). Biological media used in graft replacement 
applications that aren’t autologous are harvested from allogenic specie specific cells (19). 
Clinically targeted applications generally avoid xenogenic cells that are isolated from a 
different donor species. This general avoidance is contributed to biological incompatible 
surface signatures that often hinder normal in situ wound healing (5).  
1.9  Scaffolding 
Most tissue engineering strategies have focused on creating a scaffold using biomaterials 
to direct specific cell types to organize into the three dimensional (3D) structures and 
perform differentiated function on the target tissue (12). There are specific requirements 
for designing a regenerated organ. The tissue for example must match the structure and 
function of the desired organ (37). Traditionally the polymer scaffolds are engineered to 
mimic the natural ECM of the body. However, most engineered scaffolds don’t poses 
specific ligands needed to transduce to signaling to host cells during wound healing (32). 
The technique used to manufacture engineered bioresorable polymers into a suitable 
scaffold depends on end application. Scaffolding generally involves 3 steps (37). The 
principal step is heating the polymer to its melting temperature or its glass transition 
temperature where the mechanical properties change significantly from the solid state to 
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something more malleable. The second step requires dissolving the polymer into organic 
solvents and lastly the melt solution is incorporated and leached into porogens like 
geletain microsheperes. These properties have adverse characteristics associated 
biocompatibility and its physical properties. Long term survival has implications for 
scaffolding using polymer based materials (37). Notably, the local drop in pH due to the 
release of acidic degradation products from some implants may cause tissue necrosis or 
inflammation. Particles from the scaffold formed after long term implantation of a 
scaffold or due to micro-motion at the implantation site may elicit an inflammatory 
response (37).  
1.10 Bioreactors 
As mentioned previously one of the chief obstacles during in vitro development of cell-
polymer devices is obtaining uniform cell seeding at high densities and then maintaining 
nutrient transport to the cells inside their static culturing vehicle (18).  To achieve desired 
spatial and temporal distributions of cells and molecular characteristics affecting cellular 
function, cell culture conditions should provide control over hydrodynamic and 
biochemical factors in the cell environment (9, 10). Several dynamic cell seeding and 
culture techniques have been developed to ensure uniform tissue regeneration (20, 22, 
35). Simultaneously comparing dynamic to static cultures conditions, rates of mass 
transfer are favored by the continuous movement of contents ubiquitously supplying 
nutrients at an unrestricted rate for well-mixed conditions (33). Most importantly these 
methods have the capabilities to scale up cell cultivation (18, 23). The most primitive of 
the scalable bioreactors is the spinner flask system (37). Three dimensional polymer 
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scaffolds are fixed to needles suspended from the cap of the flask. They are then exposed 
to a uniform well mixed cell suspension. There has been limited success of this approach 
using hESCs (21). This study demonstrated a 15-fold expansion in total number of EB-
derived cells cultured for 21 days in a stirred flask compared to a fourfold expansion in 
static cultures. There are other limits to the spinner system. Ideally the spinner rate has to 
be well adjusted to minimize cell damage during high shear environments. Other types of 
bioreactors include rotating cell culture systems RCCS developed by NASA to make 
microgravity environments (33).  There  are some important functional features  
associated with their design (33, 37). Principally, RCCSs rotate around a horizontal axis 
that is well characterized by extremely low fluid shear stress. The media maintains its 
oxygenation by passive diffusion of dissolved gases from the vessel chamber. This setup 
makes chamber reactors devoid of gas bubbles and gas/fluid interfaces (8, 37). The 
yielding flow patterns of these dynamic systems are laminar with mild mixing seen. The 
slow rotation for this type of vessel produces a low shear environment (8). Another 
advantage is the vessel’s accommodating geometry (33). These vessels are designed to 
have a high media volume to cell culture ratio thus promoting excellent gas exchange. 
There are two types of RCCS bioreactors both designed and created by Synthecon (7). 
They are the High Aspect Rotating Vessel, HARV and the Slow Turning Lateral Vessel, 
STLV. The major difference besides their design geometry include the fashion in which 
culture mixing is achieved which is a function of the vessel geometry. The aspect ratio 
(diameter/length) of the HARV system is higher than the STLV such that the cells and 
subsequent aggregates spend less time in contact with the vessel wall (33). Numerous 
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contacts and collisions with the vessel wall of the STLV prevent the formation of large 
cellular aggregates that tend to result in necrotic centers. Another advantageous feature 
seen on contemporary bioreactor designs include a perfusion component (7, 10, 11, 33, 
37). Here the additional component affords a continuous flow condition which is crucial 
for the costly maintenance of hESC. The culture medium is pumped from a reservoir to 
through an oxygenator to the vessel chamber and is re-circulated back to the reservoir. 
The flow rate for cell survival is specific to the cell type. The entire process is maintained 
in sterile conditions. When compared to static cultures, the perfusion system has 
demonstrated a significant enhancement of cell viability and proliferation of multi-potent 
differentiating cells (7, 10). These systems maybe useful for the development of complex 
tissue structures such as hEBs as well as the study of the effects of mechanical 
stimulation on cell viability and differentiation because their culturing environment is 
similar to native in vivo embryonic development (28, 37). 
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Chapter 2 – Literature Review  
 
The following section is intended to provide background information for the reader on 
the methodologies used to complete our research. There are several published studies that 
address the induction of hESCs to mesoderm cells through the hEB model (10).  Here we 
present a brief overview.  In vitro hESC differentiation commonly requires an initial 
spontaneous formation of spherical cell clusters in suspension. These were described 
previously as human embryoid bodies, hEBs. The developing hEBs are composites of all 
three primary germ layers endoderm, ectoderm, and mesoderm. Standard methods for 
hEB generation include hanging drops, liquid suspension, and methyl cellulose culture 
(28).  The techniques have had some success maintaining the balance between desirable 
ESC aggregation necessary for proper EB formation and the prevention of EB 
agglomeration. Agglomeration has previously been reported negatively for exhaustive 
cell death and poor differentiation (10, 37). It was noted that agglomeration may be 
avoided by readying the aggregates in static culture (7).  Methods for controlling EB 
formation and cell proliferation have reached for bioreactors as described in a previous 
chapter. As reported in table 1, a sample of successes for generating hEBs have been 
reported for using dynamic culturing especially the STLV. 
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Table 1 – Previous Parameters for Established Research groups: Aubry, Yirme, Gerecht-
Nir (28, 8, 33) 
 
 The STLV was developed by the National Aeronautics and Space Administration and is 
characterized by EB immobility in space due to an extremely low fluid shear stress, 
approx 10-2 dyne/cm2, and oxygenation by diffusion. Previous groups have reported 
success with establishing the mesoderm as well the other germ layer by incorporating 
exogenous factors such as BMP4, bone morphogenic promoter 4, VEGF, or Activin A for 
mesoderm lineages. Others are reported below in Table 2.  
 
Mesoderm  Primary Inducers Tissue Type References 
 END-2 co-culture Cardiomyocytes 30 
 BMP4, SCF, IF3-, IL-6, GCSF Blood 25 
 VEGF Blood 6 
 BMP4 or Activin A Blood 1 
  
Table 2 – Mesoderm differentiation by primary inducers 
 
END-2, visceral endoderm-like cell line; SCF, stem cell factor; IF3-,  
Group  Cell 
Line 
Seeding 
Density (# 
of cells per 
mL) 
Initial Cell 
Seeding 
Technique 
Drive/Pump 
(RPM) 
EB Control  
 
REF. 
1 H9, 
VUB01 
0.5 E6  Collagenase and 
Dispase  5mls (1 
and .3mg/ml) 
into clumps 
12-20 / 10 SCC same 
seeding 
densities 
28 
2 H9 0.7 ± 0.1 
E6  
0.2% 
Collagenase 
/Scrapping 
passage followed 
by EB formation 
for two day 
16 / Not 
Reported 
SCC same 
seeding 
densities 
8 
3 H9 0.1 – 1.2 
E6 
.5mM EDTA 
and 1% FBS into 
clumps 
Titrated to 
suspension 
SCC same 
seeding 
densities 
33 
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Literature has shown other factors that help describe embryonic development. HoxB5-
binding site in the flk1 gene is required for expression within the vascular endothelium 
during development in murine studies (14). Most importantly, it has previously been 
shown in static culture that overexpression of HoxB5 increases the number of angioblasts 
during embryonic stem cell differentiation as determined by measuring the number of 
flk1+ cells produced during hEB mesoderm differentiation (6).  These flk1+ cells are 
present at early stages of angioblast differentiation in this system and also in lower 
frequencies of mature endothelial cells, which form primitive blood vessels (16).  
Early stages of endothelial cell differentiation from embryonic origins are under strict 
control, and many factors both intrinsic and extrinsic coordinate this process (1) . In 
particular, deletion of numerous growth factors can disrupt steps within this pathway. For 
example, lack of a single VEGF allele severely disrupts differentiation of the 
endothelium, leading to embryonic lethality short before a hEB can furnish surface 
markers to denote the different germ layers in vitro (6).  
Our working hypothesis is that HoxB5 is sufficient to increase flk1+ precursors 
and expand definitive blood born populations in embryoid bodies using a dynamic 
cultivation system that will be benefited by pulsate perfusion. This is a unique cell-
intrinsic perturbative approach to the hemangioblast differentiation pathway but has only 
been shown in static conditions using murine models (14). Here we try to prescribe the 
same event in a human hESC model, scaffoldlessly, as further progress towards clinical 
applications.   It is our aim of this initial study to establish that a pustule perfusion 
bioreactor is necessary platform to efficiently achieve scalable quantities of embryoid 
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bodies.  To prove simple efficacy of the bioreactor, we will use alkaline phosphatase, a 
stem cell membrane marker. Elevated expression of this enzyme has previously been 
demonstrated with undifferentiated pluripotent stem cells (38). Embryonic stem (ES) (8), 
embryonic germ (EG) (38) and embryonic carcinoma (EC) (8) cells, express alkaline 
phosphatase activity. There are different methods of detecting AP such as methods based 
on enzymatic reaction followed by colorimetric or fast red violet dye, fluorescent 
detection and immunostaining (38). We will show that the Embryoid bodies cultured in 
both static and dynamic culturing systems are viable methods for culturing and are 
therefore consistent with previous studies using our methods. The fast red violet dye is an 
efficient method that we will use to determine that indeed we have embryonic germ cells 
and thus an appropriate system to eventually characterize our model.  In continuing 
studies we aim to demonstrate that HoxB5 is a direct transcriptional activator of flk1 in 
hESC derived hEBs. Our future efforts will show the spontaneous distribution of  
differentiated germ cells and then compare this to our model through flow cytometry that 
over expression of HOXB5 is required to upregulate flk1 receptor during mesoderm 
development. 
 
 
 
 
 
 
 
  
 
 
 
26 
 
 
 27 
 
 
CHAPTER 3 - Methods and Materials 
 
3.1 Cell Culture 
Mouse embryonic fibroblast cell culture: Mouse embryonic fibroblasts (MEFs)  
were isolated from day 14 pregnant mice (Jackson Labs) and cultured in DMEM-High  
Glucose with 10%FBS, 50U/mL penicillin, and 50µg/mL streptomycin, as previously  
described. MEFs were mitotically inactivated with Mitomycin C (Sigma Chemical  
Co., St. Louis, MO), and seeded to 6-well dishes at a density of 300,000 MEFs per well.  
MEFs were allowed to attach and grow for a minimum of three days prior to hESC  
seeding.   
3.2 Human Embryonic Stem Cell Culture 
 An  NIH-approved human embryonic stem cell lines BG01v (Bresagen, Athens, GA) 
were routinely cultured in standard hESC medium that included Dulbecco’s minimal 
essential medium/Ham’s F12 medium (DMEM/F12), 2 mM L-glutamine, 0.1mM 
minimal essential medium (MEM) nonessential amino acids, 50 U/mL penicillin, 50  
µg/mL streptomycin (all from Gibco, Gaithersburg, MD), 4 ng/mL basic fibroblast 
growth factor (bFGF; R&D Systems, Minneapolis, MN) and 20% (Knockout Serum 
Replacment™ (KSR), as previously described. HESC line BG01v is a rapidly dividing, 
karyotypically aneuploid cell line, whereas hESCs are a normal diploid line.  
3.3 Alkaline Phosphatase Assay  
All harvested cultures were subjected to alkaline phosphatase (AP) activity, as a general 
positive indicator of pluripotencey and their germ cell derivatives, with a Vector®  
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Red Alkaline Phosphatase Kit (Vector Laboratories, Burlingame, CA), as previously  
described [17]. In brief, the AP staining mixture was prepared according to manufacturer  
directions, using 0.1 M Tris buffer (Sigma) and stepwise addition and mixing of each AP  
kit reagent. Next, medium from each sample used for AP staining was aspirated  
completely away and samples were then rinsed with PBS to remove any excess media or  
culture debris. Following this, 1 mL of the pre-prepared AP staining solution was added  
to each sample, which were then kept in complete darkness for a minimum of 30 minutes.   
After 30 minutes, AP stained samples were viewed and phase contrast images recorded  
using a Nikon TE 2000-E inverted microscope.   
3.4 Embryoid Body Formation  
Upon reaching confluence, cells were harvested enzymatically with 1mg/ml type IV 
collagenase, clumps were mechanically lifted from the petri dish and collected for initial 
seeding in the bioreactor at 2.5 x 105 cells/mL in standard hESC medium lacking bFGF. 
Embryoid bodies (EBs) were formed for static culture at the same density using the 
hanging droplet method where each 20 uL drop contained at least 5,000 cells. The 
droplets were left undisturbed for 3 days. On day 3 hEBs were collected and transferred 
to agrose-coated petri dishes were they remained in suspension following the time course 
of the bioreactor. Media was changed every three days.  
3.5 STLV Bioreactor Set-up and function  
The perfused STLV system included an auto-claved 30-ml-wisde chamber., variable 
speed motor drives with tachometers, a culture tank, a peristaltic pump, and a silicone 
membrane oxygenator (all from Synthecon, Texas) All components were connected using 
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flexible silicone tubing. The medium outlet was used was covered using a dialysis 
membrane with a 100 kDa molecular weight cut off  at the inner cylinder of the perfused 
STLV to keep cells out. hESC were seeded in the bioreactor chamber at approximately 
0.5 million cells per mL in hESC medium without bFgF. The bioreactor was set to rotate 
at 17 rpm. The perfusion flow was set to renew all the medium in the chamber within 
24hrs (10 rpm).  
3.6 Blood Gas Analyzer Sampling 
Media samples throughout the study were sampled from the various test cases at day 5 
and 10: Static culture of hEB and the Bioreactor reservoir, freshly made media was our 
control. The samples were evaluated for pH, their electrolyte values (k+, Na+, Cl-), and 
metabolite vales (Glucose and lactic Acid) using gas a blood gas analyzer, ABL 725 
(Radiometer, West Sussex, UK) 1 mL of media per sample is required 
3.7 Viability Cell Count & Morphology  
The hEBs were harvested from either static cultures or the STLV. The hEBs were 
manually counted. To count hEBs, 10 mls of suspension were pooled for the two 
conditions (static and STLV) and counted under an inverted microscope. A Cell 
proliferation assay was completed using MTT (4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide. A cell suspension was aliquoted to 100uL in each well of 
96 well plate. 100uL of MTT (5mg/ml, Invitrogen) were added to each sample containing 
well for 4 hrs at 37 degrees. Well plates were centrifuged and MTT was aspirated. 500uL 
of .04M HCL in isopropanol was added for solubilization. Absorbance was recorded at 
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570nm in a spectrophotometer. Background was subtracted using a reference wavelength 
of 630-750nm.     
CHAPTER 4 - Results 
 
Our initial experiments focused on developing an appropriate dynamic culture system 
that would support hESCs differentiation of hEBs to mesoderm specific cell types. For 
our 10 day time course we report that the STLV system is sufficient for our future 
studies. When compared to static culturing the STLV system provided a better platform 
for propagating these structures. This is demonstrated by the staining of the AP surface 
receptors during the two test constraints (static and STLV). The more intently stained 
hEBs showed during the dynamic culturing can be interpreted as more viable than the 
static culture because of their vibrant staining versus the less intently stained static 
cultures. The assay for apoptosis (MTT Assay) showed very little activity for both case 
suggesting both methods are suitable for hEB propagation with no fear programmed cell 
death due to environmental constraints. Regarding the cell count, 2000 hEBs were 
formed initially by hanging drops. 500 were placed into static culture, and approx 1500 
were placed in the STLV. Upon harvesting hEBs were manually counted with 
approximately 40 hEBs recovered for static culture and approx 120 were harvested from 
the STLV. We looked at the metabolic activity of the culture systems. Using a blood gas 
analyzer we were able to obtain metabolic activity such as glucose concentration and 
lactic acid concentration. We also looked into other parameters of the gas analyzer 
including electrolyte levels such as calcium, sodium and chloride levels. Lastly the 
analyzer provided the pH, which was evaluated at the time of sample collection. Charts 
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are shown below.  
  
              
 
  
                       
 
  
Figure 1 – Confluent BGO1V 
colonies at 10x magnification 
Figure 2 – Confluent BGO1V 
colonies at 20x magnification. 
Figure 3 – Confluent BGO1V colonies 
at 40x magnification. 
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Figure  4 – 10 day old AP 
Stained SCC BGO1V 
hEBs at 10x  
             magnification. 
 
Figure  5 – 10 day old AP 
stained SCC BGO1V 
hEBs at 20x  
             magnification. 
 
Figure  6 – 10 day old AP 
stained SCC BGO1V 
hEBs at 40x  
             magnification. 
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Figure  8 – 10 day old  AP 
stained STLV BGO1V 
hEBs at 20x  
             magnification. 
 
Figure  7 – 10 day old  AP 
Stained STLV BGO1V 
hEBs at 10x  
             magnification. 
 
Figure  9 – 10 day old  AP 
stained STLV BGO1V hEBs 
at 40x  
             magnification. 
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Figure  10 – 10 day old  
SCC BGO1V hEBs 
histological slides at 10x  
             magnification. 
 
Figure  12 – 10 day old  
SCC BGO1V hEBs 
histological slides at 40x 
             magnification. 
 
Figure  11 – 10 day old  
SCC BGO1V hEBs 
histological slides at 20x  
             magnification. 
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Figure 15 -10 day old  STLV 
BGO1V hEBs histological 
slides at 40x 
           pH of media  
 
Figure 13 -10 day old  STLV 
BGO1V hEBs histological 
slides at 10x 
Figure 14 -10 day old  
STLV BGO1V hEBs 
histological slides at 20x 
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Figure 16 – time 
course,  pH 
             Partial Pressure                of O2 content  
 
Figure 17 – time 
course, pO2 
Figure 18 – time 
course, cK+ 
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Figure 21 – time 
course, cCl- 
Figure 20 – time 
course, cCa+ 
Figure 19 – time 
course, Na+ 
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Figure 22 – time 
course, cGlu 
Figure 23 – time 
course, cLac 
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 Blood Gas 
Bioreactor Data pH pO2 (mmHg) 
Control 7.518 194 
SCC, Day 5 7.392 188 
SCC, Day 10 7.145 176.3 
Bioreactor, Day 5 7.443 186.3 
Bioreactor, Day 
10 7.414 185.2 
 
 
 
 
 Electrolyte Values 
Bioreactor Data cK+ (meq/L) Na+ (meq/L) cCa+ (mmol/L) cCl- (meq/L) 
Control 3.6 147 0.58 127.5 
SCC, Day 5 3.5 156.5 0.705 136 
SCC, Day 10 3.4 155 0.63 134 
Bioreactor, Day 5 3.5 152 0.63 133 
Bioreactor, Day 
10 3.5 152.5 0.63 132 
 
 
 
 
 Metabolite Values 
Bioreactor Data cGlu (mg/dL) cLac (mmol/L) 
Control 236 0 
SCC, Day 5 216 2.8 
SCC, Day 10 217 3.1 
Bioreactor, Day 5 219.5 1.35 
Bioreactor, Day 
10 218.5 1.3 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3 – Time Course, Blood Gas Values  
Table 4 – Time Course, Electrolyte Values 
Table 5 – Time Course, Metabolite Values 
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CHAPTER 5 - Discussions, Conclusions and Future Directions 
 
Traditional methods for creating the hEBs by hanging drops have relied  on the tension of 
the media suspending the cell cluster to establish adhesive molecular behavior in vitro 
(28). This system worked for our needs establishing the initial structure. We left the hEBs 
for three days before transferring them to an agrose coated petri dish used to culture the 
hEBs in static culture or before they were seeded into our dynamic culturing vessel. It is 
our findings we received less hEBs than what we put in. Some of the hEBs most likely 
did not properly aggregate during the hanging drop formation. Some of the poor yield can 
be contributed to the STLV functionality. It was designed by NASA to recapitulate an 
immobilized suspension culture, characterized by low shear forces during free fall 
rotation of the cells (32, 33). Here these forces help maintain the aggregates by shear 
mixing such as in a stirred vessel reactor or as in a HARV. The mixing in the STLV is 
extremely mild and shear forces are negligible. This keeps cells in an un-aggregated state. 
Dissociated hESC suspensions do not survive in any condition because they are 
susceptible to apoptosis upon cell detachment and dissociation (17).  
There are limited quantities of studies regarding bioreactors used to enhance hEB 
formation under dynamic conditions and there are even fewer studies that utilize STLV 
bioreactor. In future studies regarding differentiation it would be important to completely 
investigate the induction of hEBs as it poses to be the limiting step in this instigation. 
During our bioreactor optimization, 60 hEBs were plated by hanging drop and less than 
100,000 cells were recovered and found viable based on counting using a hemacytometer. 
100,000 cells recovered is the equivalent of 20 hanging drops assuming that there is 
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100% recovery with complete cell disassociation in Trypsin. Reasonably for 1 million 
cells, which is, the minimum required to run one sample needed for flow cytometry 
future investigations. This would create a need of excess of 200 hanging drops. This 
equates out to over 600 hanging drops needed to run analysis on standard static culturing 
conditions for the hEBs. Our seeding concentrations for the bioreactor followed the 
concentration for making hanging drops to be consistent. The 250,000 cells needed per 
ml require at least 7500000 cells for our 30mL STLV. This equates out to a minimum of 
1500 hanging drops. This does not account for optimizing parameters during flow 
cytometry. This could take an immeasurable amount of cells. Though the methods will 
change for our studies the platform will remain. Our bioreactor the STLV with pulsitile 
perfusion is an excellent vehicle to conduct these investigations using hEBs. The media 
within the culturing vessel is exchanged completely within a 24 hour period depending 
on the size of the culturing vessel and the rate at which the peristaltic pump operates. 
This is beneficial because literature has already substantiated maintenance and viability 
of hESCs is dependent on frequent exchange of media during cultivation (9). There is 
other variability within our initial study that needs to be adjusted for a successful study. 
While isolated using established methods independently, it is useful to compare 
experimental results between two distinct cell lines. Therefore in future research an 
additional cell line would also be needed (20). This new cell line would be investigated 
consecutively preceding our initial study with the BGO1V. The BGO1 variants are a 
good start for our investigation because they are characterized by their rapidly dividing 
behavior in culture.  This is beneficial during the actual cell culture of the hESCs because 
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of the requirement of material (cells) needed to conduct the study. Other cell lines such as 
H9s are known to have longer doubling times and are not as robust in culture (26). 
Having an additional cell line would be useful to determine if our study’s behavior can be 
applied evenly to all hESC lines.  
A huge benefit to this study is our ability to monitor the activity of the cultures through 
their enzymatic  activity.  What we found through our studies is that the bioreactor was 
more capable at maintaining at homeostasis when compared to static cultures. This is 
shown from the data depicting the blood gas analyzer.  For known incoming media we 
would in future studies be able to investigate which parameters pertaining to the 
bioreactor (the pump rate and/or rotation rate) influence the accumulation or de-
accumulation of nutrients. Another feature that needs to be investigated are the effects of 
lactate build up in culture oh hESC.   
A major benefit of the dynamic system is its feasibility to  introduce exogenous factors 
during culture in a time sequestered manner. This would follow our model of 
embryology, where local factors during development such as VEGF are invoked (6). The 
media bottle would facilitate the process by allowing a facile interchange of drugs, 
transiently, into the system that would model after a specific development embryo-
logically.  We would be able to control the process of differentiation with out disturbing 
the hEBs.  One reservation would be the optimization needed to establish proper drug 
dosage.  Dosage studies would need to be developed to show the efficacy of delivery in 
this fashion. 
Our major intent is to eventually characterize the resultant cultures under flow cytometry. 
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This method provides a high throughput quantitative measurement of the differentiating 
cells in our study. There are some major caveats with this analysis that needs to be 
addressed before the study can progress. As mentioned in a previous section cell 
clumping is a result from the disassociation of the hEBs using Trypsin. Commonly 
literature has substantiated that Trypsin is the enzymatic treatment of choice for placing 
the hEB in single cell suspension. Using a .5M concentration of the enzyme cells mostly 
go into suspension with some mechanical agitation. Other groups have overcome this 
perturbation by using a larger filter to subtract the un-disassociated aggregates from the 
suspension. The group used a 45um mesh to filter through the clumps. This method will 
be applied to future studies of our investigation. Once the cells are in single suspension 
for flow parameters must be established for analysis. The problem associated with 
unconjugated labels is they often have non specific binding issues that result in a nosey 
analysis. This can be overcome by using conjugated markers that only require 1 facile 
step for labeling.  Markers that should be used routinely to continue this study include: 
Mesoderm: early mesoderm marker CD31/pecam1 as well as Flk1+ which is also a 
marker hemangioblast; Endoderm: CD184/CXCR4 a definitive endoderm marker as well 
as beta catenin which is an early marker; Ectoderm: early marker nestin and neuronal 
marker MAP2. All of these markers are available conjugated through BD. By running 
samples that are conjugated we reduce the overwhelming need for control regarding 
unconjugated labels. This is a more efficient way to characterize the hEBs for the limited 
amount of material produced from each experimental run.  Originally we would need to 
run our sample plus a positive control, for an unconjugated specimen a sample with the 
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secondary fluorescent tag to determine non-specific binding. Initially 24 samples were 
required for single color analysis. This included 6 positive control samples known to emit 
florescence when tagged with the respective markers, at most 6 samples for secondary 
labeled cell to determine auto-fluorescence, it could be less depending on if the primary 
antibodies have some overlap in what they are stabilized in, 6 samples for analysis from 
the bioreactor and yet another 6 samples for the statically cultured hEBs. This would 
require approach our limit of materials (cells) for one experimental run using the 
bioreactor as well as static culture materials. By switching to conjugated antibodies we 
reduced our sample need, we wouldn’t need to look at non specific binding thereby 
reducing our sample size to 18 which in turn would require 6 million cells for the 
bioreactor and another 3 million for the static culture. What we can’t escape are the 
positive controls for flow cytometry. Here we can use cell lines that are aren’t embryonic 
but are able to bind the conjugated antibodies to produce known results. What will 
remain the same is the analysis of the media using the blood gas analyzer.  
From the graphs seen regarding the metabolic and electrolyte activity we were able to 
substantiate that at least for this run the bioreactor is only slightly more efficient than the 
static culture. We expect that these results will change during subsequent investigations. 
We expect the lactate acid concentration to decrease in the bioreactor with future studies 
due to the induction of the hEBs similar to that of the static culture. To address a time 
frame for future experiments briefly readdress the experiment with regard to time.  
Culturing of hESC is no small task. Traditionally methods used to culture included 35mm 
petri dishes that yield approx 400 cells with mixed heterogeneity due to the feeder layer. 
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It would be best to increase the petri dish size to a 100 cm dish where the hESC can be 
passaged enzymatically in bulk. Culturing takes about two weeks to get the density 
needed for an experimental run. Inducing the hEB may take about a week between 
making the hanging drops and allowing the cell suspension to aggregate sufficiently. We 
attempted to culture the hEB dynamically in culture for 15 days and this is sufficient for 
early marker detection and our initial study. However, our initial study only address part 
of the picture and we would need to culture these cells dynamically for an excess of a 
month to achieve later differentiated mesoderm cells needed to bring our study into 
fruition. Characterizing the hEBs should take another week, to perform the intended 
analysis presented in this study. Therefore in the future this initial study should take 
approximately two months.  
Preceding the initial study future researchers would need to look into HOXB5 and 
investigate its direct role in endothelial differential. Pathway analysis would look into 
over expressing HOXB5 transcriptional through transfection and then blocking the VEGF 
receptor Flk1 to investigate its direct role in the differentiation progression. Specific 
questions that would need to be addressed are the driving mechanisms in HOXB5 and 
VEGF. Currently there are no reported successes identifying the underlying relationship 
of HOXB5 in hESCs. A schematic model would need to be created as a road map for the 
signal trasnduction involved in future studies. 
The aim of this introductory study was to provide a reasonable model for describing the 
embryonic events associated with primitive blood island formation. Though the study had 
some inherent problems associated with methodologies used to conduct the study it does 
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provide a platform on which to continue the study and progress to the larger aim of 
addressing the role of HOXB5 on human development.  
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APPENDIX 
 
Week 1: Preparing Media and MEFs 
• Start on a Thursday 
• Make Mef media: 1 Liter Preparation:  
 
1. Remove 100mls DMEM from a new 1 liter bottle. Hyclone cat# 16777-176. 
2. Add 100mls FBS to the 900mls of DMEM. 
3. Add 10mls Penicillin/Streptomycin. Invitrogen cat# 15070-063. 
4. Add 10 mls L-Glutamine. Invitrogen cat# 25030-081. 
5. Store at 4°C for 2 weeks. 
• A.  Make Mitomyocin C to inactivate Mefs: 
 (Note:  Mitomycin C is highly toxic, Use 2.0 mg pre-measured powdered  
50 
 
mitomycin C per vial (Sigma, Cat#M4287). 
1. Dissolve contents of vial in 200.0 ml complete MEF medium. 
2. Stock can be stored in the dark at 4°C, for up to 6 weeks, or -20°C for long-
term storage. 
3. Used Mitomycin MUST be neutralized by addition of 15ml Clorox per 500ml 
mitomycin C solution. Swirl waste and allow to sit 15 minutes before 
discarding. 
 
• B. Thawing Mouse Embryonic Fibroblast  (Week 1 – Friday) 
1. Remove vial of MEF’s from Liquid Nitrogen. 
2. Crack open lid under biosafety cabinet to release pressure. Close tightly again. 
3. Cells are thawed rapidly by hand rotating the cryovial in a 37°C water bath. 
4. Spray vial with 70% Ethanol, and dry with kimwipe. 
5. Working in a biological safety cabinet, transfer the thawed MEF cells to a 
sterile 5 ml conical centrifuge tube.  
6. Swirling slowly, drop-wise add 5.0 ml of complete medium to the cell 
suspension.  
7. Add an additional 5.0 ml of complete medium. 
8. Centrifuge at room temperature at 200 X g for 4 minutes. (200g =1000rpm on 
bench top 5810R) Resuspend the cells in 10 ml medium. Pipette well before 
removing aliquot for counting. 
9. Count the viable cell number using trypan blue. Record dead cell number for 
reference of freeze/thaw procedures. Viability is usually >95%.   
10. Seed T75 flasks at approximately 1.0 X 106 cells (depending on the doubling 
time of the cell stock) per flask. Use 15ml MEF medium per flask. Swirl to 
ensure even distribution. 
11. Incubate flasks at 37°C in a 5% CO2 environment. 
12. MEFs should be 90-95% confluent, in the T75 flasks, 3 days after the initial 
thawing of the cells. 
 
• C. Mitomycin C Inactivation   
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1. MEFs should be at 90-95% confluencey in the T75 flasks 3 days after the 
initial thawing of the cells 
2. Check each flask individually by observing under microscope to ensure 
cell growth and culture sterility. 
3. In a biosafety cabinet, aspirate medium from T75 flasks and add 8mls of 
mitomycin C solution (10µg/ml). 4. Incubate treated flasks for 2 hours at 37°C, 5% CO2.  Work in sets of no more than 6 flasks at a time 
5. After 2 hour inactivation of cells, aspirate off the mitomycin C solution. 
(neutralize waste with Clorox). 
6. Wash each flask 5 times with 8ml PBS+/+ (Dulbeccos /Hyclone Inv.cat # 
SH30264.02). 
7. Aspirate the PBS+/+ and wash the cells with 8ml PBS-/- ( Dulbeccos /Inv. 
cat# 14190-144) per flask 
8. Add 2.0ml per flask of 0.05% trypsin/EDTA solution (Gibco, cat# 
25300-054). 
9. At room temperature monitor the degree of cell detachment. Rock and 
gently tap the flask.  MEF’s are trypsin sensitive Do Not Over Expose.(1 
minute) 
10. When cells sufficiently detach from the flask, normally 1-2 minutes, add 
3.0 ml complete medium to each flask to inactivate the trypsin.  Rock to 
disperse. 
11. Pool cell suspensions from 1 – 6 flasks into 2 x 15 ml conical tube. 
12. Add 5ml MEF medium to first flask and rinse out cells. Transfer this same 
5ml to the subsequent flasks and pool with cell suspension. 
13. Discard Flasks. 
14. Adjust the volume in each tube to 12.0 ml with MEF medium. 
15. Centrifuge cells at 200 x g for 4 minutes at room temperature. 
16. Resuspend cell pellets with MEF medium and pool into 1 x 50ml tube.  
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17. Centrifuge cells at 200 x g for 4 minutes at room temperature. 
18. Resuspend cell pellet in 20ml MEF medium, use 10 ml pipette and ensure 
to resuspend fully.  
19. Centrifuge cells at 200 x g for 4 minutes at room temperature. (This has 
given a total of 9 washes for cells: 6 before trypsin, 1 at trypsinization, 2 
post trypsinization in MEF medium). 
20. Resuspend the cell pellet first in 10.0 ml of complete medium and then 
add medium to final volume of 20ml, mixing again vigorously before 
counting.   
21. Count cells with trypan blue. (Remove 10ul of cell suspension and add 
10ul of Trypan Blue)  Mixing is critical to get an accurate cell count.  
22. Seed 7.2E6 mefs per 100mm dish 
23. Allow the MEF’s to settle for 4 days. Change medium on day 4. They 
are ready to use. 
• D. Make Stem cell Media (Week 2 – Monday)  
1. 38.5 ml DMEM/F12 (Gibco, Cat. No. 11320-033) 
2. 10ml  KSR (Knockout Serum Replacement; Gibco Cat. No. 10828-028) 
3. 0.5ml Penicillin/Streptomycin (Gibco, Cat.No. 15070-063, 1:100 dilution) 
4. 0.5ml L-Glutamine (Gibco, Cat. No. 25030-081, 1:100 dilution) 
5. 0.5ml Non-Essential Amino Acids (Gibco, Cat. No. 11140-050, 1:100 
dilution) 
6. 8µl bFGF [basic Fibroblast Growth Factor or FGF2] per 50ml of medium 
(Sigma; 4.0ng/ml Cat. No. F-0291 made to stock of 25µg/ml in BSA)  
7. 5ul β-Mercaptoethanol  (Sigma M7522 . 5 µl of 1M stock/50ml) 
8. Filter sterilize through 0.22micron before use to ensure sterility. 
• E. Thawing hESCs (Week 2 – Wed) 
1. Pre-equilibrate aged MEFs. Using at least 3 day old MEF plates, aspirate 
off medium and replace with 10mls 20% KSR medium.  
2. Place dish at 37ºC until ready to plate out cells. 
3. Wearing protective face visor and cryo gloves, remove cryovials from 
liquid nitrogen. 
4. Crack open lid under biosafety cabinet to release pressure. Close tightly 
again. 
5. Cells are thawed rapidly by hand rotating the cryovial in a 37°C water 
bath until only small ice pieces remain. 
6. Spray vial with 70% Ethanol, and dry with kimwipe. 
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7. Working in a biological safety cabinet, transfer the thawed cells to a sterile 
15 ml conical centrifuge tube.  
8. Swirling slowly, drop wise add 10 ml of 20% KSR medium to the cell 
suspension.  
9. Centrifuge at room temperature at 200 X g for 4 minutes. (200g =1000rpm 
on bench top Sorvall Legend RT) 
10. Resuspend pellet in 10mls KSR medium. 
11. Aspirate medium from pre-equilibrated dishes and plate thawed cells. 
12. Check daily for colony formation. Colonies may take as long as 10-14 
days to appear 
• F.  Enzymatic Passage 
    Collagenase 1mg/ml Preparation:  
1. Weigh out 10mg Collagenase Type IV  (Gibco # 17104-019). 
2. Dissolve in 10ml of 20% KSR medium at 37ºC. 
3. Filter sterilize. Use within one week, store at 4 degrees.   
 
 Passage of Cells 
1. Using at least 3 day old MEF plates, aspirate off medium and replace with 
10 mls of 20%KSR medium. Place dish at 37ºC until ready to plate out 
cells. 
2. Add 3 ml of collagenase per 100mm dish. Place on 37ºC stage for 2-3 
minutes. Colonies can be observed rounding under dissection scope. 
3. Aspirate off collagenase and add 1ml 0.05% Trypsin. 
4. Allow trypsin to contact cells for no more than 40 seconds, aspirate off. 
5. Add 1 ml of 10% FCS DMEM/F12 to dish and under scope begin to 
gently pipette to knock off and break up cell clumps. 
6. Place harvested cells in 15ml tube containing 8 ml 20% KSR medium. 
7. Add fresh medium to the dish and wash off any remaining trypsinized 
cells, add to 15ml tube.  * (Once feeder layer begins to roll or break it is 
time to stop. The best cells seem to be those that come off first so don’t try 
hard to collect everything on the feeder layer or those that remain attached 
to plate.) 
8. Spin harvested cells for 4 minutes at 200g at room temperature. 
9. Resuspend pellet in 20% KSR medium in 5mls per 100mm plate 
trypsinized. 
10. Count cells by taking 10µl cell suspension and mixing with 10µl Trypan 
blue. Fill one chamber of a 0.1mm deep hemacytometer. Count 4 corner 
boxes on grid. Ensure minimum of 100 events counted. Divide total by 
number of boxes counted. Take this number to x 104, then multiply by 2 
for trypan dilution and finally by total volume of cells in 15ml tube. This 
will give total cell count. ie. 200 cells counted over 4 boxes from 12 ml 
starting cell volume = (200 / 4) x 104 x 2dil x 12ml. 
11. Aspirate medium from pre-equilibrated dishes and plate cells at 900,000 
cells per 100mm dish in 10 ml medium. Place at 37°C 5% CO2.  Move 
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plate cross wise on shelf to evenly distribute cells. Feed every day with a 
50% medium change until ready to passage again in 3-4 days. 
• G.  Preparing the Bioreactor (Follow Instructions Provided By  
                   Synthecon) 
1. Described briefly  Use the Liquinox (mild soap) to wash the reactor 
2. Allow bioreactor to remain in soapy water 10 mins 
3. Rinse well and allow to soak overnite 
4. Carefully follow the 2nd day rinse instructions 
5. Wrap individual components times three and autoclave follwing 
protocol 
6. REMOVE PROMPTLY FROM AUTOCLAVE 
7. Keep wrapped until ready to seed bioreactor 
8.  Schematic Provided by the maufactuer will inform you of proper 
setup. 
• H. Agrose Plates for hEBs (Week 2 – Thursday) 
1. Weigh out 0.5g Agarose and place in sterile glass bottle. 
2. Add 100mls DMEM/F12, replace cap on bottle but do not tighten. 
3. Microwave and bring to boil. 
4. Confirm all agarose is in solution by swirling.  
5. Repeat microwave until in solution then allow to boil for 15 seconds to 
ensure sterility. 
6. Allow to cool to room temperature before use. 
7. Can be stored at 4°C for 4 weeks. Melt in microwave and cool before 
each use. 
Preparation of Agarose plates 
1. Once Agarose has cooled after boiling, work in biosafety or laminar 
flow cabinet. 
2. Lay out 100mm Petri dishes. Keep plastic sleeve to store prepared 
dishes. 
3. Using 25ml pipette, cover the bottom of 1 Petri dish at a time. 
4. Swirl agarose to evenly distribute then pipette up excess agarose. 
5. Continue onto subsequent Petri dishes. 
6. Allow dishes to set for 10 mins at room temperature. 
7. Replace dishes into plastic sleeve and store at 4°C until ready to use. 
 Equilibrating Agarose plates 
1. When Embryoid Bodies (EBs) are ready to be grown in suspension 
prepare and equilibrate agarose plates. 
2. Remove desired number of plates from plastic sleeve at 4°C. 
3. Add to each plate 10ml DMEM/F12. 
4. Place plates at 37°C and allow at least 40 mins to warm. 
5. Aspirate off DMEM/F12 and replace with pre-warmed medium of 
choice for EB culture. 
 
•  I.  Making human Embryoid Bodies (Week 2 – Friday) 
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1. Prepare 100mm Petri dishes by adding 10ml sterile PBS++ and pre-
warming at 37°C. 
2. Once you have desired colonies in sufficient quantity to convert to 
Embryoid Bodies (EB’s), dissociate cells as if passaging. 
3. After cells have been centrifuged following wash, count cells. 
4. Resuspend at 2.5x105 cells/ml in 15%FBS 5% KSR medium. This will 
allow for good quality EB formation. Depending on pathway chosen for 
EB’s to follow this number may be altered. 
5. Open lid of Petri dish and place on level surface. 
6. Onto inner side of  lid pipette drops of 5000 cells in 20µl. 
7. Carefully replace lid onto Petri dish containing PBS++. Do not allow drops 
to roll together. 
8. The cells will now grow in suspension in hanging drops. Less than 
50% will aggregate successfully. 
9. After 3 days of culturing hanging drops prepare for static cultures 
10.  Place appropriate amount in the agrose dishes 
11.  Gently suspend remaining hEBs into 10mL to load in the bioreactor. 
• J. Experiment 
1. Take Samples at day 5, and 10, 15 (1ml). And evaluate them for 
viability using trypan blue. 
2. At day 15, fix cells and label them for appropriate markers (details 
below) 
• K.  4%PFA / 4% Sucrose in PBS Preparation:  
1. Work in a fume hood and wear gloves, paraformaldehyde is TOXIC, 
see MSDS. 
2. Weigh out 4g paraformaldehyde (PFA) and add to glass beaker. 
3. Weigh out 4g sucrose and add to PFA in glass beaker. 
4. Add 75ml distilled water and place on heated stirrer to dissolve. 
Temperature 56°C. 
5. Add 2 drops of 1M sodium hydroxide from transfer pipette. 
6. Once all has gone into solution add 10 ml of 10X PBS++. 
7. Using pH meter or paper check pH is between 7.2 and 7.4. Adjust 
accordingly. 
8. Make up volume to 100mls with Distilled water. 
9. Store at 4°C and use within 1 week.  
• L. Fixing of Cells 
1. Work in a fume hood. 
2. Wash cells 1 times in PBS plus Ca & Mg (++). Use aspirator to remove 
and a transfer pipette to add PBS. Be very gentle, cells will dislodge 
easily. 
3. Add PFA solution to just more than cover bottom of well or dish. 
4. Sit at room temperature for 15-20 min. 
5. Wash cells 3 times in PBS ++. 
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6. Store fixed cells at 4°C until ready to stain with chosen markers. 
• M. IMMUNOFLUORESCENCE-FLOW CYTOMETRY  
a. Wash cell sin PBS.  
b. Resuspend at 106 cells/ml using PBS-1%BSA (kept sterile to avoid 
contamination).  
c. Distribute 100ul of cell suspension/polystryrene transparent disposable 
5-ml tube (12x75mm).  
d. To assess autofluorescence of the cells (i.e., fluorescence of the cells 
without addition of any exogenous fluorochrome), prepare one tube 
with cells only.  
e. Set proper controls (ideally, a cell line that you know expresses the 
surface Ag of interest, a cell line that you know does not express the 
surface Ag of interest, your experimental cells currently studied 
stained with an isotype-matched negative control: for example if you 
are studying KIT expression using an mAb which is a mouse anti-
human KIT IgG1, you need to use a mouse IgG1 Ab targeted against 
nothing in particular, so it’s an isotype matched, since both are IgG1s, 
both raised in the mouse, but targeted against different epitopes.  
f. Block each sample with 1 ml of PBS-1%BSA. This is the blocking 
step so be creative! Some people block samples in the presence of the 
serum of the species in which the secondary Ab has been produced. 
For example, if your primary Ab is unlabeled and is a mouse anti-
human, your secondary has to be “something” anti-mouse (labeled) 
let’s say, goat or sheep, then add 10% of normal goat or normal sheep 
serum. Usually, people block for 30 min at +4oC.  
g. WORK AT +4oC (on ice or in the fridge, to avoid receptor 
internalization). 
h. ALL BUFFERS, mAb  solutions, washes need to be performed using 
ice-cold solutions.  
i. Spin tubes for 10 min at 1200 rpm.  
j. To get rid of the supernatants, quickly revert tubes and catch the last 
drop of liquid by tapping them on layers of wipes before you put them 
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back up. Then, put tubes back up and run the bottom of the tubes 
quickly over a rack, to resuspend cell pellets.  
k. Add primary Ab (conjugated or not) at the right concentration (usually 
1-10 ug/ml) in 100 ul/tube. Incubate 15-30 minutes on ice (or fridge) (I 
do 12 min) IN THE DARK IF FLUO).  
l. Wash twice by adding 1 ml of ice-cold PBS/BSA and spin for 10 min 
at 1200 rpm.  
m. Eliminate sups and resuspend pellets as indicated above.  
n. After the final wash, add 200 ul of sheath fluid (actually for Fran’s and 
Julie’s flow cytometer, you need to add more, ideally one ml, but 500 
ul is fine).  
o. Acquire promptly. Ideally you want to stain cells with Propidium 
Iodide (PI, FL2) to exclude dead cells from your analysis. Then, you 
have to make sure that your primary is in FL1 or FL3!! Analysis could 
be performed on a different day.  
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